Journal profile · ONCOLOGY
Cancer Medicine
ISSN 2045-7634 · John Wiley and Sons Ltd · UNITED STATES
Cancer Medicine: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.42; fully open access; APC about USD 4,970; median 188 days to acceptance (162 articles, last 24 months); acceptance rate 15% (journal website); 1,016 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Medicine is published by John Wiley and Sons Ltd and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Cancer survivorship and care and Ferroptosis and cancer prognosis, together about 20.4% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Aims and ScopeCancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:Clinical Cancer ResearchTranslational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer BiologyMolecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery Cancer PreventionBehavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreachBioinformaticsGene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, research methods papers, and brief communications, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper. We aim to be a truly global forum for high-quality cancer research, and we think that the best research should be published and made widely accessible as quickly as possible. Cancer Medicine publishes papers submitted directly to the journal and those referred from a select group of prestigious journals published by Wiley-Blackwell. List available here. Open Access and CopyrightAll articles published by Cancer Medicine are fully open access: immediately freely available to read, download and share. All Cancer Medicine articles are published under the terms of the Creative Commons Attribution License which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Copyright on any research article in a journal published by Cancer Medicine is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified. Further information about open access license and copyright can be found here. Peer
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editor-in-chief Stephen TaitPublisher website
Editorial board by country: 14 in mainland China (about 20%); most named United States 28, Mainland China 14, India 10, United Kingdom 8, Italy 2 (69 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine8.6%
- Cancer survivorship and careMedicine6.2%
- Ferroptosis and cancer prognosisMedicine5.6%
- Global Cancer Incidence and ScreeningMedicine5.4%
- Lung Cancer Treatments and MutationsMedicine5.3%
- Head and Neck Cancer StudiesMedicine4.7%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology4.4%
- Hepatocellular Carcinoma Treatment and PrognosisMedicine4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPMCEmbaseCASCAB AbstractsCurrent ContentsPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.42LetPub ·
- Impact factor (publisher)
- 3.5Publisher website ·
- Impact factor (publisher) 2025
- 3.5Publisher website ·
- CiteScore 2026-06
- 5.7LetPub ·
- CiteScore (publisher)
- 5.7Publisher website ·
- CiteScore (publisher) 2025
- 5.7Publisher website ·
- SJR 2026-06
- 1.16LetPub ·
- SNIP 2026-06
- 1LetPub ·
- h-index
- 34LetPub ·
- h-index
- 125OpenAlex ·
- i10-index
- 5,022OpenAlex ·
- 2-year mean citedness
- 3.82OpenAlex ·
- Self-citation rate
- 2.9%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 924LetPub ·
- Articles per year (publisher) 2025
- 928Publisher website ·
- Downloads per year (publisher) 2025
- 3,415,133Publisher website ·
Articles by year OpenAlex count · 9,912 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 799 | 799 | 257 |
| 2025 | 1,016 | 1,016 | 3,183 |
| 2024 | 1,165 | 1,165 | 7,936 |
| 2023 | 1,295 | 1,295 | 14,789 |
| 2022 | 1,080 | 1,080 | 15,782 |
| 2021 | 844 | 844 | 17,027 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
188 daysMedian, submission to acceptance · P25–P75 123 days – 259 days
- Acceptance to online
- median 14 days (162 articles)
- Submission to online
- median 210 days
- Sample
- 162 articles with submission and acceptance dates (2,026 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 19 weeksLetPub ·
- Acceptance rate (publisher)
- 15%Publisher website ·
- Acceptance rate (publisher) 2025
- 15%Publisher website ·
- Submission to first decision
- 7 daysPublisher website ·
- Submission to first decision 2025
- 7 daysPublisher website ·
- Submission to acceptance 2025
- 169 daysPublisher website ·
- Acceptance to publication 2025
- 17 daysPublisher website ·
- Submission to publication (journal-reported)
- about 19 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 4,970 / GBP 3,050 / EUR 3,760 | Yes | CC BY | |
| OpenAlex | USD 4,700 / EUR 3,560 / GBP 3,050 | — | — | |
| LetPub | USD 4,070 / GBP 2,640 / EUR 3,080 | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Reference style
- Author–date
- First submission
- Free format: the journal's layout is not required
Policy excerpts from the journal's websitePublication ethics, Open access, Peer review, Preprints
- Publication ethics 5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS
Editorial Review and AcceptanceCancer Medicine accepts papers that are relevant to our readership and reflect valid science ie. conclusions drawn need to be substantiated by the data, but novelty, insight and impact are not paramount. Except where otherwise stated, manuscripts are single-anonymised peer reviewed. Papers will only be sent to review if the handling editors determine that the paper m…
Source ↗Publisher website ·- Open access
Free format submission. Model summary
Cancer Medicine now offers Free Format submission for a simplified and streamlined submission process.
Source ↗Publisher website ·- Peer review
Single-anonymized peer review. Model summary
Cancer Medicine follows a single-anonymized peer review process.
Source ↗Publisher website ·- Preprints Preprint policy:
Preprints allowed. Model summary
Wiley believes that journals publishing for communities with established pre-print servers should allow authors to submit manuscripts which have already been made available on a non-commercial preprint server. Allowing submission does not, of course, guarantee that an article will be sent out for review. It simply reflects our belief that journals should not rule out reviewing a paper simply becau…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- John Wiley and Sons Ltd
- Country or region
- UNITED STATES
- Language
- English
- ISSN
- 2045-7634
- Latest issue on the website
- Volume 15, Issue 9 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Cancer Medicine
What CAS zone is Cancer Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Medicine is in Zone 3 of Medicine, and in Zone 3 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Medicine?
The latest impact factor listed by LetPub is 3.42; CiteScore 5.7, h-index 125.
How long does peer review take at Cancer Medicine?
Based on the dates recorded on 162 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 188 days (interquartile range 123–259 days); authors report an average review time of about 19 weeks; the journal's website gives an acceptance rate of 15% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Cancer Medicine?
According to the journal's author guidelines: Reference style: Author–date; First submission: Free format: the journal's layout is not required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Cancer Medicine based?
Of the 69 board members whose country the journal's board page names, 14 (about 20%) are in mainland China; the countries named most often are United States (28), Mainland China (14) and India (10). Counted from the institutions listed on the board page; for reference only.
Which databases index Cancer Medicine?
According to LetPub and DOAJ records, Cancer Medicine is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Web of Science, MEDLINE, PMC, Embase, CAS, CAB Abstracts and Current Contents; that list has not been checked against each database.
Is Cancer Medicine open access, and what is the APC?
Cancer Medicine is a fully open-access journal. APC about USD 4,970.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .